If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFlowtech Fluid. Regulatory News (FLO)

Share Price Information for Flowtech Fluid. (FLO)

Share Price is delayed by 15 minutes
Get Live Data
59.80    2.80 (4.91%)
Bid:
57.20
Ask:
60.00
Spread: 2.80 (4.895%)
Market Cap: £48.70m
FLO Live PriceLast checked at - London Stock Exchange

Intraday Flowtech Fluid. Share Chart

Acquisition

29 Apr 2005 07:00

Flomerics Group PLC29 April 2005 29 April 2005 Flomerics Group plc ("the Company") Acquisition of Microelectronics Research & Development Limited Flomerics Group plc ("Flomerics" or "the Company"), supplier of virtualprototyping analysis software for the electronics industries announces theacquisition of the entire share capital of Microelectronics Research &Development Limited ("MicReD") for a maximum total consideration ofapproximately €2.1 million. Initial consideration is approximately €898,000, ofwhich €653,000 is payable in cash, the remaining €245,000 is satisfied by theissue of 250,663 Ordinary Shares of 1 pence each in the Company ("OrdinaryShares"), 80% now and 20% after 1 year. The deferred consideration is dependenton the financial performance of MicReD in 2005 and 2006. MicReD is a Hungarian based company and was formed in 1997 as a spin-off fromBudapest University of Technology. MicReD employs 13 people all located inBudapest and is led by the Chief Executive Officer, Marta Rencz. The managementteam of MicReD will all remain with the business. Its primary product is theT3Ster (pronounced Trister) - instrumentation and software used for measuringthe thermal performance of chip packages. Existing customers include Philips,Infineon, ST Microelectronics, Intel, Samsung and IBM. In the year to 31December 2004 MicReD had audited income of approximately €538,000 and made aprofit before tax of €288,000. In the previous year the unaudited turnover wasapproximately €123,000. The net assets at 31 December 2004 were €234,000. The semiconductor companies that make up the main target market for the T3Sterrepresent a significant, and strategically important, sector of the Flomerics'customer base. The use of the T3Ster enables them to evaluate and improve thethermal performance of chip-package designs - often alongside the complementaryuse of Flomerics' thermal analysis software. Just as the need for Flomerics'products is driven by the increasing miniaturisation and thermal densities ofelectronics devices - so exactly the same trends are driving the need for theT3Ster. The acquisition is thus strongly synergistic with Flomerics' current corebusiness, and represents a significant step for Flomerics towards providing acomplete thermal-design solution for its customers. In order to satisfy part of the initial consideration application has been madefor 200,530 new ordinary shares of 1p each to be admitted to trading on AIM witheffect from 5 May 2005. Following admission the issued share capital of theCompany will be 14,847,110 Ordinary Shares of 1p each. Commenting on the transaction David Tatchell, Flomerics' Chief Executive said "This is an important first step in delivering on our strategy of growing theCompany by acquisition in a way that complements our organic growth plans. I amdelighted to welcome into the Group the world-leading expertise that the MicReDteam bring. The T3Ster has many applications in markets where Flomerics is wellestablished, and we believe therefore that there is great potential to expandthe business." Marta Rencz said "We are very excited to be a part of the Flomerics group.Flomerics is the acknowledged standard setter in this field and theirinfrastructure will enable us to maximise the potential of our products." For further information please contact: David Tatchell Chief Executive 020 8487 3000Chris Ogle Finance Director & Company Secretary Buchanan Communications 020 7466 5000Tim Thompson / Nicola Cronk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th Apr 202010:01 amRNSUpdate on Results Announcements
16th Apr 202012:48 pmRNSIssue of Equity and Total Voting Rights
2nd Apr 20207:00 amRNSBusiness Update - COVID-19;Notice of Final results
27th Mar 20202:46 pmRNSDirectorate Changes
6th Mar 202012:15 pmRNSHolding(s) in Company
17th Feb 20207:00 amRNSDirector/PDMR Shareholding
14th Feb 20203:12 pmRNSHolding(s) in Company
13th Feb 20203:58 pmRNSHolding(s) in Company
13th Feb 20207:00 amRNS2019 Trading update & restructuring activities
7th Feb 20204:44 pmRNSHolding(s) in Company
6th Feb 20206:07 pmRNSHolding(s) in Company
20th Jan 20204:13 pmRNSHolding(s) in Company
15th Jan 20204:38 pmRNSHolding(s) in Company
14th Jan 20207:00 amRNSTrading Update - for the year to 31 December 2019
17th Dec 20195:43 pmRNSHolding(s) in Company
5th Dec 20194:41 pmRNSSecond Price Monitoring Extn
5th Dec 20194:35 pmRNSPrice Monitoring Extension
2nd Dec 20194:40 pmRNSSecond Price Monitoring Extn
2nd Dec 20194:35 pmRNSPrice Monitoring Extension
27th Nov 20191:51 pmRNSDirector/PDMR Shareholding
25th Nov 20194:40 pmRNSSecond Price Monitoring Extn
25th Nov 20194:35 pmRNSPrice Monitoring Extension
22nd Nov 20194:40 pmRNSSecond Price Monitoring Extn
22nd Nov 20194:35 pmRNSPrice Monitoring Extension
30th Oct 20199:30 amRNSDirector Share Option Award
28th Oct 20197:00 amRNSDirector/PDMR Shareholding
22nd Oct 20197:00 amRNSTrading update -nine month period to 30 Sept 2019
30th Sep 20194:10 pmRNSCorrection: Director/PDMR Shareholding
30th Sep 201911:32 amRNSDirector/PDMR Shareholding
24th Sep 20197:00 amRNSHalf-Year Report - six months ended 30 June 2019
15th Aug 20191:56 pmRNSDirector/PDMR Shareholding
14th Aug 201912:08 pmRNSSecond Price Monitoring Extn
14th Aug 201912:02 pmRNSPrice Monitoring Extension
30th Jul 20197:00 amRNSIssue of Equity and Total Voting Rights (TVR)
18th Jul 201911:29 amRNSDirector/PDMR Shareholding
16th Jul 201912:07 pmRNSSecond Price Monitoring Extn
16th Jul 201912:02 pmRNSPrice Monitoring Extension
12th Jul 20197:00 amRNSGroup Trading Update & Notice of Half-Year results
13th Jun 201911:25 amRNSIssue of Equity and Total Voting Rights
5th Jun 201910:56 amRNSResults of Voting AGM - 5 June 2019 and TVR
5th Jun 20198:46 amRNS2019 Annual General Meeting Statement
16th May 20197:00 amRNSDeferred Consideration and Total Voting Rights
8th May 20191:35 pmRNSAudited Results - Notice of Annual General Meeting
7th May 201911:34 amRNSHolding(s) in Company
17th Apr 20195:21 pmRNSHolding(s) in Company
16th Apr 20197:00 amRNSPreliminary results - year ended 31 December 2018
16th Apr 20197:00 amRNSQ1 2019 Trading Update
8th Apr 20195:04 pmRNSHolding(s) in Company
26th Mar 20197:00 amRNSHolding(s) in Company
18th Mar 201911:29 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.